156 participants
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-12-11
- Start Date:
- 2025-12-10
- Completion:
- 2028-12-10
Conditions
- Pancreatic Cancer, Adult
Interventions
- DRUG
No Results Yet